<DOC>
	<DOCNO>NCT02301806</DOCNO>
	<brief_summary>To investigate whether single administration sitaglitpin restore acute endothelial dysfunction ameliorate impaired increase number endothelial progenitor cell ( EPCs ) oral glucose loading patient T2DM . To compare effect sitagliptin glimepiride endothelial function evaluate flow-mediated vasodilatation ( FMD ) number circulate EPCs patient T2DM .</brief_summary>
	<brief_title>Effects Sitaglpitin Endothelial Function During OGTT T2DM</brief_title>
	<detailed_description>Acute chronic improvement endothelial function expect pleiotropic effect DPP-4 inhibitor . A randomized , prospective , open-labeled , parallel design . The duration treatment sitagliptin glimepiride 12 week . The number study center single ( Dokkyo Medical University Hospital ) . Participants randomize two treatment group ; ( ) 50mg sitagliptin ( N=15 ) ( b ) 1mg glimepiride ( N=15 ) . Anti-Hyperglycemic effect expect similar accord study</detailed_description>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Provision inform consent study specific procedure Type II diabetes inadequate glycaemic control ( 6.5 % ≦HbA1c＜9.0 % ) Age 20 80 year old No history use antihyperglycemic drug No history cardiovascular complication No treatment treatment stable dos lipidlowering , antihypertensive , antiplatelet agent least 3 month prior randomization 4.5 % ≤ fasting FMD baseline &lt; 8.0 % ・Type I diabetes Pregnancy Liver disease ( hepatic enzyme three time upper limit normal range ) Impairared kidney function ( serum crearinine great 1.3 mg/dl men , 1.2 mg/dl woman ) Cigarette smoker Contraindications glimepiride sitagliptin Active proliferative diabetic retinopathy</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>